DE69833509T2 - Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation - Google Patents

Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Download PDF

Info

Publication number
DE69833509T2
DE69833509T2 DE69833509T DE69833509T DE69833509T2 DE 69833509 T2 DE69833509 T2 DE 69833509T2 DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T2 DE69833509 T2 DE 69833509T2
Authority
DE
Germany
Prior art keywords
alkyl
oder
aryl
und
ist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833509T
Other languages
German (de)
English (en)
Other versions
DE69833509D1 (de
Inventor
R. Walter Pompton Plains BISHOP
J. Joseph Guilford CATINO
J. Ronald Maplewood DOLL
Ashit Upper Montclair GANGULY
Viyyoor Parsippany GIRIJAVALLABHAN
Paul Basking Ridge KIRSCHMEIER
Ming Fanwood LIU
L. Loretta Millington NIELSEN
L. David Moorestown CUTLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833509(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69833509D1 publication Critical patent/DE69833509D1/de
Application granted granted Critical
Publication of DE69833509T2 publication Critical patent/DE69833509T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69833509T 1997-12-22 1998-12-21 Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Expired - Lifetime DE69833509T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US996027 1997-12-22
US14352998A 1998-08-28 1998-08-28
US143529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US181969 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (2)

Publication Number Publication Date
DE69833509D1 DE69833509D1 (de) 2006-04-20
DE69833509T2 true DE69833509T2 (de) 2006-10-26

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833509T Expired - Lifetime DE69833509T2 (de) 1997-12-22 1998-12-21 Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation

Country Status (25)

Country Link
EP (1) EP1041985B1 (cg-RX-API-DMAC7.html)
JP (1) JP4502503B2 (cg-RX-API-DMAC7.html)
KR (1) KR100700907B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129431C (cg-RX-API-DMAC7.html)
AR (1) AR017440A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317697T1 (cg-RX-API-DMAC7.html)
AU (1) AU756762B2 (cg-RX-API-DMAC7.html)
BR (1) BR9814419A (cg-RX-API-DMAC7.html)
CA (1) CA2315693C (cg-RX-API-DMAC7.html)
CL (1) CL2007001889A1 (cg-RX-API-DMAC7.html)
CO (1) CO5080764A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298511B6 (cg-RX-API-DMAC7.html)
DE (1) DE69833509T2 (cg-RX-API-DMAC7.html)
DK (1) DK1041985T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255196T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0102473A3 (cg-RX-API-DMAC7.html)
IL (1) IL136462A0 (cg-RX-API-DMAC7.html)
MY (1) MY137303A (cg-RX-API-DMAC7.html)
NO (1) NO326832B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504928A (cg-RX-API-DMAC7.html)
PE (1) PE20000042A1 (cg-RX-API-DMAC7.html)
PT (1) PT1041985E (cg-RX-API-DMAC7.html)
SK (1) SK285584B6 (cg-RX-API-DMAC7.html)
TW (1) TW581763B (cg-RX-API-DMAC7.html)
WO (1) WO1999032114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
WO1997036583A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
AU3215197A (en) * 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Also Published As

Publication number Publication date
HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 (en) 2003-07-28
DE69833509D1 (de) 2006-04-20
ES2255196T3 (es) 2006-06-16
CL2007001889A1 (es) 2008-01-11
CA2315693C (en) 2010-11-30
SK285584B6 (sk) 2007-04-05
EP1041985B1 (en) 2006-02-15
CN1284875A (zh) 2001-02-21
CO5080764A1 (es) 2001-09-25
IL136462A0 (en) 2001-06-14
CN1129431C (zh) 2003-12-03
WO1999032114A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
AU756762B2 (en) 2003-01-23
SK8982000A3 (en) 2001-04-09
MY137303A (en) 2009-01-30
TW581763B (en) 2004-04-01
PT1041985E (pt) 2006-07-31
PE20000042A1 (es) 2000-02-17
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
KR100700907B1 (ko) 2007-03-29
NO20003229D0 (no) 2000-06-21
KR20010033452A (ko) 2001-04-25
NO326832B1 (no) 2009-02-23
JP4502503B2 (ja) 2010-07-14
DK1041985T3 (da) 2006-06-19
NZ504928A (en) 2004-12-24
CZ298511B6 (cs) 2007-10-24
EP1041985A1 (en) 2000-10-11
NO20003229L (no) 2000-08-22
ATE317697T1 (de) 2006-03-15
AR017440A1 (es) 2001-09-05
AU1907299A (en) 1999-07-12
JP2001526224A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
DE60032226T2 (de) Verfahren zur induktion von krebszellentod und tumorregression
US6333333B1 (en) Methods for treating proliferative diseases
DE69625518T2 (de) Wirkstoff zur behandlung neurodegenerativer störungen
DE69329073T2 (de) In liposomen verkapseltes taxol und verwendungsverfahren
DE19814838C2 (de) Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE60216139T3 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
DE60130017T2 (de) Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
DE69017302T2 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69821520T2 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
DE60214846T2 (de) Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
DE69628645T2 (de) Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums
JP4502503B2 (ja) 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
WO2002020521A1 (de) Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems
DE19542281A1 (de) Verwendung von Epinastin für die Behandlung von Schmerzen
DE68923151T2 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE69531722T2 (de) Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
DE60316297T2 (de) Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
DE68907392T2 (de) Dysmnesie modifizierende Arzneimittel.
EP0859613B1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE60011060T2 (de) Virus behandlung
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
DE60318561T2 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
DE60110628T2 (de) Antiphlogistische mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition